ICOSAGEN AS

Their core work

Icosagen is an Estonian biotech SME based in Tartu that specializes in mammalian cell biology, with particular depth in CHO (Chinese Hamster Ovary) cell systems — the dominant production platform for biopharmaceuticals worldwide. They contribute industrial expertise in recombinant protein expression and cell line development, bringing hands-on manufacturing capability that academic labs typically lack. In parallel, they work in clinical immunoprofiling, applying molecular diagnostics to stratify patients with autoimmune diseases. Their role in two MSCA training networks positions them as an industrial host for early-stage researchers, bridging university science and commercial bioprocessing practice.

What they specialise in

How they've shifted over time

Both H2020 projects launched simultaneously in 2015, so there is no temporal shift to trace within this dataset — the organization entered EU-funded research with two distinct but complementary tracks at the same moment. The biomanufacturing track (eCHO Systems) concluded in 2018, while the immunodiagnostics track (PROFILE) ran through 2019, suggesting a slight drift toward clinical applications in the latter period. No keyword data is available to refine this picture further; the evolution pattern is inferred from project scope and end dates alone.

With both projects concluding by 2019 and no later H2020 activity recorded, it is unclear whether Icosagen has continued EU-funded collaboration — a potential partner should verify their current research engagement and service portfolio directly.

How they like to work

Icosagen has never led an H2020 project, joining exclusively as participant or third party — a pattern consistent with SMEs that contribute specialized industrial capacity rather than coordinating broad research agendas. They operate within large MSCA training networks, which typically involve 8–15 partners across multiple countries, meaning they are comfortable with complex, multi-institutional consortia. This profile suggests they work best when given a defined technical scope: cell line work, assay development, or researcher hosting, rather than overall project management.

Despite only two projects, Icosagen has accumulated 24 unique consortium partners across 10 countries — a reach that reflects the inherently multinational structure of MSCA training networks. No strong geographic concentration is visible from the data, pointing to broad European exposure rather than a regional cluster.

What sets them apart

Icosagen occupies an unusual niche as one of very few Estonian private biotech companies active in H2020, combining industrial-scale CHO biomanufacturing with immunodiagnostic assay expertise — a combination rarely found in a single SME of this size. Their Tartu base, adjacent to the University of Tartu ecosystem, likely gives them access to academic talent pipelines that larger Western European CROs cannot replicate at the same cost. For consortium builders, they offer a credible industrial anchor in the Baltic region with demonstrated experience hosting doctoral researchers under MSCA rules.

Highlights from their portfolio

• PROFILE
  The sole funded project (EUR 226,265), structured as a European Industrial Doctorate — the most intensive MSCA format — focused on immunoprofiling autoimmune patients, confirming Icosagen's role as a genuine industrial research site, not just a name on a grant.
• eCHO Systems
  Participation in this network on CHO mammalian systems biotechnology signals deep biopharmaceutical manufacturing expertise, positioning Icosagen within the core infrastructure of European biologics production research.